Predictive value of phase i trials for safety in later trials and final approved dose: Analysis of 61 approved cancer drugs

Clinical Cancer Research

Volumn 20, Issue 2, 2014, Pages 281-288

  Jardim, Denis L ^a,b   Hess, Kenneth R ^a   LoRusso, Patricia ^c   Kurzrock, Razelle ^d   Hong, David S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c KARMANOS CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CHILL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MORTALITY; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG APPROVAL; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84892690026     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2103     Document Type: Article

References (21)

1. Critical role of phase 1 clinical trials in cancer treatment. American Society of Clinical Oncology. J Clin Oncol. 1997;15:853-9.
2. Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson 1, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol. 2011;29: 1728-35.
3. Soria JC. Phase 1 trials of molecular targeted therapies: are we evaluating toxicities properly? Eur J Cancer. 2011;47:1443-5.
4. Penel N, Adenis A, Clisant S, Bonneterre J. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs. Invest New Drugs. 2011;29: 1414-9.
5. Iasonos A, Gounder M, Spriggs DR, Gerecitano JF, Hyman DM, Zohar S, et al. The impact of nondrug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. Clin Cancer Res. 2012;18:5179-87.
6. Le Tourneau C, Razak AR, Gan HK, Pop S, Dieras V, Tresca P, et al.Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: A review of the literature. Eur J Cancer. 2011;47:1468-75.
7. Administration UFaD. FDA approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
8. Postel-Vinay S, Arkenau HT, Olmos D, Ang J, Barriuso J, Ashley S, et al. Clinical benefit in phase I trials of novel molecularly targeted agents: does dose matter? Br J Cancer. 2009;100:1373-8.
9. Adjei AA. What is the right dose? The elusive optimal biologic dose in phase 1 clinical trials. J Clin Oncol. 2006;24:4054-5.
10. Sleijfer S, Wiemer E. Dose selection in phase I studies: why we should always go for the top. J Clin Oncol. 2008;26:1576-8.
11. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase 1 oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010;16: 1289-97.
12. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101:708-20.
13. Parulekar WR, Eisenhauer EA. Phase 1 trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst. 2004;96:990-7.
14. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, et al. The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30:3012-9.
15. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895-904.
16. Roberts TG Jr, Goulart BH, Squitieri L, Stallings SC, Halpern EF, Chabner BA, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA. 2004;292: 2130-40.
17. Olmos D, A'Hern R P, Marsoni S, Morales R, Gomez-Roca C, Verweij J, et al. Patient selection for oncology phase I trials: A multiinstitutional study of prognostic factors. J Clin Oncol. 2012;30: 996-1004.
18. Mukherjee SD, Coombes ME, Levine M, Cosby J, Kowaleski B, Arnold A. A qualitative study evaluating causality attribution for serious adverse events during early-phase oncology clinical trials. Invest New Drugs. 2011;29:1013-20.
19. Le Tourneau C, Stathis A, Vidal L, Moore MJ, Siu LL. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol. 2010;28:1401-7.
20. Tolcher AW, Takimoto CH, Rowinsky EK. The multifunctional, multiinstitutional, and sometimes even global phase I study: A better life for phase I evaluations or just "living large"? J Clin Oncol. 2002; 20:4276-8.
21. Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer. 2008;44:19-24.